SymBio Pharmaceuticals (TSE:4582) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
37 GF Score
Price 円66.00
GF Value 円60.26
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

SymBio Pharmaceuticals Quality Rank Related Terms

TSE:4582
37GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円66.00 is trading 9.5% above its estimated GF Value™ of 円60.26. GuruFocus considers SymBio Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSE:4582:

  • Quality Rank:
  • GF Value™: 円60.26 vs. price of 円66.00 (9.5% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
37GF Score

Get the complete analysis for TSE:4582

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円66.00
Price
円60.26
GF Value